Literature DB >> 22065362

Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.

Paul Grootendorst1, Ron Bouchard, Aidan Hollis.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22065362      PMCID： PMC3307559          DOI： 10.1503/cmaj.110493

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  A comparison of United States and Canadian laws as they affect generic pharmaceutical market entry.

Authors:  E Hore
Journal:  Food Drug Law J       Date:  2000       Impact factor: 0.619

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

3.  New approaches to rewarding pharmaceutical innovation.

Authors:  Paul Grootendorst; Aidan Hollis; David K Levine; Thomas Pogge; Aled M Edwards
Journal:  CMAJ       Date:  2010-12-13       Impact factor: 8.262
  3 in total
  2 in total

1.  A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.

Authors:  Steven G Morgan; Marc-André Gagnon; Barbara Mintzes; Joel Lexchin
Journal:  Healthc Policy       Date:  2016-08

2.  The Impact of Tiered-Pricing Framework on Generic Entry in Canada.

Authors:  Wei Zhang; Huiying Sun; Daphne P Guh; Larry D Lynd; Aidan Hollis; Paul Grootendorst; Aslam H Anis
Journal:  Int J Health Policy Manag       Date:  2022-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.